학술논문
ABCL-023 frontMIND: A Phase III, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma
Document Type
Article
Author
Source
In: Clinical Lymphoma, Myeloma and Leukemia , Proceedings of the Society of Hematologic Oncology 2022 Annual Meeting. (Clinical Lymphoma, Myeloma and Leukemia, October 2022, 22:S352-S353)
Subject
Language
English
ISSN
21522669
21522650
21522650